Home » Topics » Disease categories and therapies » Substance use and poisoning

Substance use and poisoning
RSS

Orexo reports phase III data on Zubsolv for induction of buprenorphine maintenance therapy

June 25, 2014

Bunavail buccal film approved by FDA for opioid dependence

June 11, 2014

Pfizer researchers design nicotine vaccines with higher avidity

May 26, 2014

Double-blind trial finds (S)-(-)-OSU-6162 effective in treating alcohol dependence

May 9, 2014

FDA approves Evzio for the emergency treatment of opioid overdose

April 7, 2014

Medesis Pharma and CEA sign collaborative agreement

April 3, 2014

Southwest Research Institute receives contract extension for cyanide antidote

March 31, 2014

New monoclonal antibodies for the treatment of botulism disclosed

March 24, 2014

MediciNova announces start of MN-166 clinical study for marijuana dependence

March 11, 2014

Titan Pharmaceuticals and FDA discuss path forward for Probuphine

March 4, 2014

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 2, 2026.
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
Amlogenyx’s AM-805 reduces amyloid plaques in AD
BioWorld Science
The potent carboxypeptidase enzyme protective protein cathepsin A (PPCA) is known to cleave the C-terminus of amyloid-β42, responsible for aggregation and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026
Atai Therapeutics patents new 5-HT2 receptor agonists
BioWorld Science
Atai Therapeutics Inc. has identified new 5-HT2 receptor agonists potentially useful for the treatment of psychiatric disorders.